Our Blog

Digital e-Learning Programs: Instilling Confidence in Companion Diagnostic Results

Martha Townsend, Kate Clark & Kathy Morgan
March 24, 2017

The Anatomic Pathology lab has experienced monumental changes in recent years expanding the pathologist’s role beyond a cancer diagnosis to being a key contributor who delivers critical patient results defining treatment selection. The onslaught of genetic and molecular technologies and the increased availability of cancer targeted therapies has further added complexity to the pathologists’ role… Read more »

Leading Edge Advances in Genomics: Insights from AMP 2016

Martha Townsend & Kate Clark
January 5, 2017

Since its formation in 1995, the Association for Molecular Pathology (AMP) has been the premier showcase for remarkable technological advancements in the field of molecular diagnostics. The show has seen the evolution of nucleic acid testing from HIV viral load testing in 1996 to a CLIA waived PCR-based strep test in 2015 to the current… Read more »

Why Testing Matters in the World of Personalized Diagnostics: A Review of Complementary vs. Companion Diagnostics

Martha Townsend
September 8, 2016

In the world of personalized diagnostics, history does not necessarily predict the future. Following the much anticipated FDA approval of the first immuno-oncology drug Keytruda® (Merck) for NSCLC patients in October 2015 as a Companion Diagnostic (CDx) for PD-L1 testing , all eyes then went to Bristol Myers Squibb with competitor OPDIVO® as the CheckMate 057… Read more »

Straight From the Horse’s Mouth: Integrating Voice of Customer Insights into Strategy Planning

Kate Clark
July 12, 2016

Who is the ideal target customer for our product? What features will drive customers to switch to our product? When will our product be utilized in the patient treatment continuum? Where do we stand relative to our competitors? Why do customers resist adoption of our product? How do we better understand what our customers want? These are some of the key… Read more »

4 Easy Steps to Making a Splash on Social Media in the IVD Marketing Space

Christina Scalise
June 16, 2016

Do social media sites really get your company brand recognition in the diagnostics space? The answer is yes! The top two benefits of social media marketing are increasing exposure and company website traffic. Social Media Examiner1 states that 89% of all marketers revealed their social media efforts generate increased exposure for their business and 75% reporting… Read more »

What’s New in Tissue Diagnostics: Walking the USCAP Tradeshow Floor

Martha Townsend (Contributions by: Christina Scalise & Kate Clark)
May 27, 2016

On a brisk 30°F morning in March, I slipped into the most comfortable shoes I could find, to tackle a two day USCAP tradeshow tour in Boston, MA. My first impression was -WOW – USCAP is all grown up. I’ve been attending USCAP since 1999, at a time when the exhibit were in a small… Read more »

Critical Marketing “Must Haves” for a Robust Companion Diagnostic Launch

Martha Townsend and Christina Scalise, Market Ready Rx
February 11, 2015

In the last decade, tremendous attention has been placed on Personalized Medicine, a new approach using an individual’s genetic makeup to define a more targeted treatment. The value of Companion Diagnostic (CDx) tests as a class of diagnostics driving clinical management of patients is taking hold with CDx tests such as a HER2 helping positive… Read more »

The Art of Communicating Breast Cancer Diagnostics to Patients

Kate Clark (contributions by Martha Townsend and Christina Scalise)
October 14, 2014

Breast cancer. Two words that can change a life in an instant. Two words which are personal for many of us. Two words driving billions of dollars of research, diagnostic and prognostic test development, and breakthrough treatment options. So, while we have made tremendous strides in advancing the standard of care for breast cancer patients,… Read more »

Commercial Considerations When Launching a Melanoma Diagnostic

Christina Scalise, Kate Clark & Martha Townsend, Market Ready Rx
September 30, 2014

Melanoma is not only a seasonal summer cancer. The statistics are staggering. The American Cancer Society estimates more than 76,000 new melanomas will be diagnosed in the US alone this year. Melanoma rates have been rising for over 30 years with the culprit ranging from a thinning ozone layer to sun loving baby boomers now reaching the… Read more »